Dr Masato Tashiro | Director, WHO's Collborating Centre for Influenza
National Institute of Infectious Disease

• Evaluating specific challenges associated with manufacturing different vaccines
• Developing robust approaches to fully utilise production facility
• Exploring the different strategies available for ensuring quality control and regulatory compliance

Asia contains a wide variety of vaccine markets, each with different advantages due to cultural, economic and geographic differences. Identifying the right partners to develop vaccines from initial R&D through trials to commercialization requires a strategic and well defined approach.
This workshop will assist participants in understanding how to approach the Asian market for external research and development and how to successfully build a pipeline through strategic partnerships.

• Factors to consider before implementation: performance equivalency, quality, logistics and business needs
• Evaluating which single-use equipment to utilize, considering cost and which stage should be implemented first
• Examining before and after implementation for optimum efficiency

• Evaluating current development on inactivated and live molecular JE vaccine for the global population
• Tapping on lessons learnt from producing the vaccine in Asia
• Case study: Assessing the long term immunity of live attenuated Japanese encephalitis chimeric virus vaccine

• Uncovering new concepts and knowledge about innovative vaccine design; innate immunity and beyond
• Tapping on advanced technologies of immune-manipulation and delivery system in Japan
• Overcoming regulatory hurdles and harnessing the potential for adjuvants in Japan; key factors for very safe and efficacious vaccines

Leading global and Asian biotechs, pharmas and research institutes will showcase their latest vaccine developments looking for potential partners globally and across Asia. Potential partnerships run from research and development to licensing and collaboration in vaccine commercialization.